Calcium Arsenate

Dosage for Calcium Arsenate is not standardized and is determined based on the specific concentration of the extract (e.g., 1:100 w/v or 1:1000 w/v).

• Skin Prick Test (Epicutaneous): A single drop (approximately 0.05 mL) of the most dilute concentration is applied to the skin, followed by a prick through the drop.
• Intradermal Testing: If the prick test is negative, a much smaller volume (0.02 mL to 0.05 mL) of a 100-fold to 1000-fold dilution may be injected into the dermis.

Calcium Arsenate is generally not recommended for use in the pediatric population. Safety and efficacy in children have not been established. If diagnostic testing is deemed absolutely necessary by a pediatric allergist, dosages are typically reduced further, and the patient must be monitored even more stringently for systemic reactions.

Renal Impairment

Because arsenic is primarily excreted by the kidneys, individuals with Stage 3 or higher Chronic Kidney Disease (CKD) are at an increased risk of systemic toxicity if any significant amount of the drug is absorbed. While skin testing involves minimal amounts, clinicians may opt for alternative diagnostic methods (such as in vitro blood tests) in patients with severe renal failure.

Hepatic Impairment

The liver is responsible for the methylation (detoxification) of arsenic. Patients with cirrhosis or acute hepatitis may have a reduced capacity to process arsenic, potentially prolonging its presence in the body. Dosage adjustments are not standard, but caution is advised.

Elderly Patients

Elderly patients often have reduced skin turgor and delayed immune responses, which can lead to false-negative results. Furthermore, the increased prevalence of cardiovascular disease in this population makes the use of epinephrine (required if an allergic reaction occurs) more risky.

Calcium Arsenate is never self-administered. It must be administered by a healthcare professional using the following guidelines:

• Preparation: The skin (usually the forearm or back) is cleaned with isopropyl alcohol and allowed to dry.
• Application: The extract is applied to the skin at least 2 cm away from other test substances to prevent overlapping reactions.
• Observation: The patient must remain in the clinic for at least 30 minutes after administration to monitor for signs of anaphylaxis (a severe, life-threatening allergic reaction).
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

As this is a diagnostic test performed in a single session, missed doses are not applicable in the traditional sense. If a testing appointment is missed, it should be rescheduled. Do not attempt to apply any substances to your own skin at home.

An 'overdose' in the context of skin testing would involve the accidental systemic injection of the extract or the use of an excessively high concentration.

• Signs of Acute Arsenic Toxicity: Severe abdominal pain, vomiting, 'rice-water' diarrhea, a garlic-like odor on the breath, and hypotension (low blood pressure).
• Emergency Measures: If systemic absorption is suspected, the patient requires immediate hospitalization. Gastric lavage may be necessary if ingested, and chelation therapy with Dimercaprol (BAL) or Succimer (DMSA) may be initiated by a toxicologist.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt self-testing without medical guidance.

Most patients undergoing skin testing with Calcium Arsenate will experience localized reactions. These are often the intended result of the test rather than an adverse effect:

• Pruritus (Itching): Intense itching at the site of application is very common and usually subsides within 1 to 2 hours.
• Wheal Formation: A raised, pale, or skin-colored swelling at the injection site, similar to a mosquito bite.
• Erythema (Redness): A 'flare' or redness surrounding the wheal, which may feel warm to the touch.

• Persistent Local Swelling: Some patients may develop a 'late-phase' reaction where the swelling returns or worsens 4 to 8 hours after the test.
• Dermatitis: Irritation or a rash that extends beyond the immediate test site.
• Lymphangitis: In rare cases, red streaks may appear extending from the test site toward the nearest lymph node, indicating inflammation of the lymph vessels.

• Skin Necrosis: Because arsenic is toxic to cells, an excessively high concentration can cause the death of skin tissue at the site of injection, leading to a small scar.
• Vasovagal Syncope: Fainting or lightheadedness due to the stress of the needle prick or the sight of the reaction.
• Urticaria (Hives): Hives appearing on parts of the body distant from the test site.

> Warning: Stop the procedure and call for emergency help immediately if you experience any of these systemic symptoms.

• Anaphylaxis: A systemic allergic reaction characterized by a drop in blood pressure, rapid pulse, and difficulty breathing.
• Angioedema: Deep swelling of the lips, tongue, or throat that can obstruct the airway.
• Bronchospasm: Wheezing or chest tightness caused by the constriction of the airways.
• Acute Arsenic Poisoning Symptoms: If the drug is accidentally injected into a vein, symptoms may include profound weakness, metallic taste, and cardiac arrhythmias (irregular heartbeats).

Calcium Arsenate is not intended for long-term use. However, chronic exposure to arsenic (which would not occur from a single diagnostic test but could occur from repeated industrial exposure) is associated with:

• Hyperkeratosis: Thickening of the skin, especially on the palms and soles.
• Hyperpigmentation: 'Raindrop' patterns of dark spots on the skin.
• Peripheral Neuropathy: Numbness, tingling, or 'pins and needles' in the hands and feet.
• Increased Cancer Risk: Long-term arsenic exposure is a known cause of skin, bladder, and lung cancers.

There is currently no specific FDA Black Box Warning for Calcium Arsenate allergenic extracts; however, the general class of allergenic extracts carries warnings regarding the risk of severe non-fatal and fatal systemic allergic reactions. Clinicians are warned that these products should only be used by those experienced in the treatment of anaphylaxis and that patients must be observed for a minimum of 30 minutes post-injection.

Report any unusual symptoms to your healthcare provider immediately. If you notice a rash that spreads, difficulty breathing, or swelling of the face, seek emergency care.

Calcium Arsenate is a highly specialized diagnostic tool and is not a routine medication. It contains arsenic, a known human carcinogen and potent toxin. Its use is restricted to clinical environments where patients can be monitored for both allergic and toxicological responses.

No specific FDA black box warnings exist for Calcium Arsenate specifically, but it falls under the general warnings for Allergenic Extracts. These warnings state that extracts can cause severe systemic reactions, including anaphylaxis, which can be fatal. They must only be administered by physicians who are exceptionally well-equipped to manage such emergencies, including having access to oxygen, intravenous fluids, and epinephrine.

• Anaphylaxis Risk: Patients with a history of severe asthma or those currently experiencing an asthma flare-up are at a much higher risk for a fatal reaction to allergenic extracts.
• Arsenic Toxicity: Even in small doses, arsenic can interfere with cellular respiration by inhibiting the pyruvate dehydrogenase complex. While the amount in a skin test is minute, systemic absorption must be avoided.
• Cardiovascular Stability: Patients with unstable angina or recent myocardial infarction (heart attack) may not tolerate the physiological stress of an allergic reaction or the subsequent treatment with epinephrine.
• Beta-Blocker Usage: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making an allergic reaction much harder to treat.

Because Calcium Arsenate is used for diagnosis, the primary monitoring is visual and clinical:

• Immediate Observation: Monitoring the skin for 15 to 30 minutes for the 'wheal and flare' response.
• Vital Signs: Baseline blood pressure and heart rate should be taken before and after the test in high-risk patients.
• Long-term Monitoring: Is generally not required for a single diagnostic test, but if toxicity is suspected, urine arsenic levels (24-hour collection) may be ordered.

Calcium Arsenate does not typically affect the central nervous system in the doses used for skin testing. However, if a patient experiences a vasovagal reaction (fainting) or a systemic allergic reaction, they should not drive until they have fully recovered and been cleared by a physician.

There is no direct interaction between alcohol and Calcium Arsenate skin testing. However, alcohol consumption can cause vasodilation (widening of blood vessels), which might theoretically increase the size of a skin test reaction or mask a systemic reaction. It is best to avoid alcohol for 24 hours before and after the test.

As this is a one-time diagnostic procedure, 'discontinuation' is not applicable. However, if a patient begins to show signs of a systemic reaction during the test, the procedure must be stopped immediately, and the substance should be wiped from the skin.

> Important: Discuss all your medical conditions with your healthcare provider before starting Calcium Arsenate, especially if you have heart disease, asthma, or are taking blood pressure medications.

• Thiol-containing Medications: Drugs like Dimercaprol (BAL) are used to treat arsenic poisoning because they bind to arsenic. If a patient is currently taking these, the diagnostic test will be rendered useless as the arsenic will be neutralized before it can elicit an immune response.
• Live Vaccines: While not a direct chemical interaction, administering an allergenic extract alongside a live vaccine (like the MMR or Varicella vaccine) can complicate the assessment of any adverse reactions, as both can cause systemic inflammatory responses.

• Beta-Adrenergic Blockers: As mentioned, these drugs can interfere with the effectiveness of epinephrine. If a patient on beta-blockers has an anaphylactic reaction to Calcium Arsenate, the standard treatment may fail.
• ACE Inhibitors: Some studies suggest that patients on ACE inhibitors (e.g., lisinopril) may have more severe allergic reactions due to the inhibition of the breakdown of bradykinin, a vasodilator.
• Tricyclic Antidepressants (TCAs): These can potentiate the effects of epinephrine, leading to dangerously high blood pressure if epinephrine is needed to treat an allergic reaction.

• Antihistamines: Drugs like loratadine (Claritin), cetirizine (Zyrtec), and diphenhydramine (Benadryl) must be stopped several days before the test. They block the H1 receptors on the skin, which will prevent the 'wheal and flare' reaction from occurring, leading to a false-negative result.
• H2 Blockers: Medications like famotidine (Pepcid) can also partially suppress skin test reactions and should be discontinued 24-48 hours prior to testing.
• Systemic Corticosteroids: Long-term use of prednisone can suppress the immune system's response to the allergenic extract, potentially masking a positive result.

There are no known direct food interactions with Calcium Arsenate. However, if the patient is being tested for a food-related arsenic sensitivity, they should follow the specific fasting or dietary instructions provided by their allergist to ensure the baseline skin state is stable.

• St. John's Wort: May affect the metabolism of many drugs, though its effect on a localized skin test is likely minimal.
• High-Dose Vitamin C: Some evidence suggests that very high doses of Vitamin C can interfere with the methylation of arsenic in the liver, though this is primarily a concern in chronic exposure rather than diagnostic testing.

• Urine Arsenic Tests: If a patient undergoes a skin test and then immediately has a urine arsenic test, there is a remote possibility of a slight elevation, though the amount used in skin testing is typically too small to significantly alter lab results.

For each major interaction, the strategy is usually to discontinue the interfering medication (like antihistamines) for a specific period before the test.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any allergy or blood pressure medications.

Calcium Arsenate must NEVER be used in the following circumstances:

• History of Anaphylaxis to Arsenic Compounds: If a patient has previously had a life-threatening reaction to any form of arsenic, re-exposure via skin testing is strictly prohibited.
• Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume (FEV1) of less than 70% of their predicted value are at an extreme risk of fatal bronchospasm during allergenic testing.
• Acute Systemic Infection: Testing should not be performed if a patient has a fever or active infection, as the immune system is already primed, increasing the risk of an exaggerated or systemic reaction.
• Active Dermatitis at Test Site: If the skin is broken, infected, or inflamed (e.g., severe eczema or psoriasis), the test cannot be accurately performed or interpreted.

• Pregnancy: While not an absolute contraindication, the risk of a systemic reaction (which could cause fetal hypoxia) usually outweighs the benefit of diagnostic testing during pregnancy.
• Cardiovascular Disease: Patients with significant heart disease must be evaluated carefully, as they may not tolerate the stress of a reaction or the medications used to treat it.
• Recent Vaccination: It is generally advised to wait at least 1-2 weeks after a vaccination before performing allergenic skin tests.

Patients who are sensitive to Calcium Arsenate may also react to other inorganic arsenic salts, such as Lead Arsenate or Sodium Arsenite. There is no known cross-sensitivity between Calcium Arsenate and common food proteins (like nuts or shellfish) unless the food itself is contaminated with arsenic.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing or administering Calcium Arsenate.

Calcium Arsenate is classified as Pregnancy Category C (by historical standards). There are no adequate and well-controlled studies in pregnant women. Arsenic is known to cross the placenta and is a recognized teratogen (a substance that causes birth defects) in animal studies, where it has been linked to neural tube defects and fetal death. In humans, chronic arsenic exposure is associated with increased risks of miscarriage and stillbirth. Diagnostic testing with Calcium Arsenate should only be performed during pregnancy if the potential benefit clearly outweighs the potential risk to the fetus, which is rarely the case for elective diagnostic procedures.

Inorganic arsenic is excreted into breast milk, although usually at low levels. The primary risk during breastfeeding is not the arsenic itself (given the tiny amount used in a skin test) but the risk of the mother having a systemic allergic reaction that requires medications incompatible with breastfeeding. If testing is necessary, the mother may be advised to 'pump and dump' for 24 hours following the procedure as a precaution.

Calcium Arsenate is not FDA-approved for use in pediatric patients. Children have a higher surface-area-to-volume ratio and may be more susceptible to the toxic effects of arsenic if systemic absorption occurs. Furthermore, the psychological stress and physical discomfort of skin testing are often managed with alternative methods in children.

Clinical studies of Calcium Arsenate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the most dilute end of the concentration range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

As the kidneys are the primary route for arsenic elimination, patients with renal impairment must be monitored for signs of systemic accumulation. While the dose in a skin test is small, the reduced clearance in patients with a GFR (Glomerular Filtration Rate) below 30 mL/min warrants extreme caution.

In patients with severe hepatic impairment (Child-Pugh Class C), the ability to methylate (detoxify) arsenic is compromised. These patients should be monitored for signs of acute arsenic toxicity, such as gastrointestinal distress or neurological changes, even after a localized skin test.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have underlying kidney or liver issues.

Calcium Arsenate acts as a diagnostic antigen. Its molecular mechanism involves the formation of hapten-protein complexes. Once the $AsO_4^{3-}$ ion enters the local tissue, it binds to endogenous proteins. These complexes are then captured by Langerhans cells (specialized immune cells in the skin) and presented to T-lymphocytes and IgE-primed mast cells. If the patient has been previously sensitized, this triggers degranulation, releasing histamine and other mediators that cause local vasodilation and edema (the wheal and flare).

• Onset of Effect: The immediate hypersensitivity reaction typically peaks within 15 to 20 minutes of administration.
• Duration of Effect: The local wheal and flare usually resolve within 1 to 4 hours, although a late-phase reaction can occur 6 to 12 hours later.
• Tolerance: Repeated skin testing in the same area can lead to a localized 'tachyphylaxis' or reduced responsiveness, so subsequent tests must be performed on different skin sites.

| Parameter | Value |

|---|---|

| Bioavailability | <1% (Epicutaneous); >90% (Systemic/Oral) |

| Protein Binding | 90-95% (primarily to albumin and hemoglobin) |

| Half-life | 10 hours (Inorganic); 30-50 hours (Methylated) |

| Tmax | 15-20 minutes (for local reaction) |

| Metabolism | Hepatic Methylation (Inorganic -> MMA -> DMA) |

| Excretion | Renal 70%, Fecal 30% |

• Molecular Formula: $Ca_3(AsO_4)_2$
• Molecular Weight: 398.07 g/mol
• Solubility: Slightly soluble in water; soluble in dilute acids.
• Structure: An inorganic salt consisting of three calcium cations and two arsenate anions. It typically exists as a white, amorphous powder in its pure form.

Calcium Arsenate is categorized as a Non-Standardized Food Allergenic Extract [EPC]. It is grouped with other allergenic extracts used for the diagnosis of sensitivities to environmental and industrial substances. It shares clinical characteristics with other inorganic diagnostic agents but is unique due to its arsenic-based chemical structure.